{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:19:24Z","timestamp":1771597164053,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02059-8","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:48:50Z","timestamp":1769593730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of dutasteride with Bacillus Calmette-Gu\u00e9rin therapy on recurrence, progression, metastasis, and survival in non-muscle invasive bladder cancer: a retrospective single-center study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-1534","authenticated-orcid":false,"given":"Ali","family":"Nebio\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9873-4920","authenticated-orcid":false,"given":"Mert","family":"Ba\u015farano\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8624-0149","authenticated-orcid":false,"given":"Murat","family":"Bozlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-0730","authenticated-orcid":false,"given":"Mesut","family":"Tek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-414X","authenticated-orcid":false,"given":"Erdem","family":"Akbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"1","key":"2059_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/TAU.2018.09.11","volume":"8","author":"MGK Cumberbatch","year":"2019","unstructured":"Cumberbatch MGK, Noon AP. Epidemiology, aetiology and screening of bladder cancer. Transl Androl Urol. 2019;8(1):5\u201311. https:\/\/doi.org\/10.21037\/TAU.2018.09.11.","journal-title":"Transl Androl Urol"},{"issue":"6 Suppl 1","key":"2059_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/J.UROLOGY.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4\u201334. https:\/\/doi.org\/10.1016\/J.UROLOGY.2005.07.062.","journal-title":"Urology"},{"issue":"3","key":"2059_CR3","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666\u201375. https:\/\/doi.org\/10.1200\/JCO.2001.19.3.666.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2059_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/IJU.IJU_320_19","volume":"36","author":"HK Moorthy","year":"2020","unstructured":"Moorthy HK, Prabhu GGL, Venugopal P. Clinical and therapeutic implications of sex steroid hormone receptor status in urothelial bladder cancer. Indian J Urol. 2020;36(3):171\u20138. https:\/\/doi.org\/10.4103\/IJU.IJU_320_19.","journal-title":"Indian J Urol"},{"issue":"2","key":"2059_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.urology.2004.03.025","volume":"64","author":"S Boorjian","year":"2004","unstructured":"Boorjian S, Ugras S, Mongan NP, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383\u20138. https:\/\/doi.org\/10.1016\/j.urology.2004.03.025.","journal-title":"Urology"},{"issue":"9","key":"2059_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/S41585-023-00761-Y","volume":"20","author":"J Chen","year":"2023","unstructured":"Chen J, Huang CP, Quan C, et al. The androgen receptor in bladder cancer. Nat Rev Urol. 2023;20(9):560\u201374. https:\/\/doi.org\/10.1038\/S41585-023-00761-Y.","journal-title":"Nat Rev Urol"},{"key":"2059_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-023-03972-4","author":"J Seok","year":"2023","unstructured":"Seok J, Kwak HJ, Kwak Y, et al. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/S12967-023-03972-4.","journal-title":"J Transl Med"},{"issue":"1","key":"2059_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/JU.0000000000001694","volume":"206","author":"D Zhu","year":"2021","unstructured":"Zhu D, Srivastava A, Agalliu I, et al. Finasteride use and risk of bladder cancer in a multiethnic population. J Urol. 2021;206(1):15\u201321. https:\/\/doi.org\/10.1097\/JU.0000000000001694.","journal-title":"J Urol"},{"issue":"3","key":"2059_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/J.EURURO.2015.08.029","volume":"69","author":"EE Morales","year":"2016","unstructured":"Morales EE, Grill S, Svatek RS, et al. Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol. 2016;69(3):407\u201310. https:\/\/doi.org\/10.1016\/J.EURURO.2015.08.029.","journal-title":"Eur Urol"},{"issue":"1","key":"2059_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/J.UROLONC.2022.09.004","volume":"41","author":"S Dekalo","year":"2023","unstructured":"Dekalo S, McArthur E, Campbell J, Ordon M, Power N, Welk B. 5\u03b1-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urol Oncol. 2023;41(1):50. https:\/\/doi.org\/10.1016\/J.UROLONC.2022.09.004.","journal-title":"Urol Oncol"},{"issue":"3","key":"2059_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMOA030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215\u201324. https:\/\/doi.org\/10.1056\/NEJMOA030660.","journal-title":"N Engl J Med"},{"issue":"13","key":"2059_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMOA0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192\u2013202. https:\/\/doi.org\/10.1056\/NEJMOA0908127.","journal-title":"N Engl J Med"},{"issue":"6","key":"2059_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","volume":"55","author":"NA Mungan","year":"2000","unstructured":"Mungan NA, Aben KKH, Schoenberg MP, et al. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55(6):876\u201380. https:\/\/doi.org\/10.1016\/S0090-4295(00)00523-9.","journal-title":"Urology"},{"issue":"4","key":"2059_CR14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/J.CLGC.2021.01.007","volume":"19","author":"MD Wissing","year":"2021","unstructured":"Wissing MD, O\u2019Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG. The use of 5-alpha reductase inhibitors and alpha-1 blockers does not improve clinical outcome in male patients undergoing radical cystectomy for bladder cancer in Quebec, Canada. Clin Genitourin Cancer. 2021;19(4):371-e3719. https:\/\/doi.org\/10.1016\/J.CLGC.2021.01.007.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"2059_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/J.EUF.2019.04.021","volume":"7","author":"SC Wu","year":"2021","unstructured":"Wu SC, Kwon D, Jue JS, et al. Androgen suppression therapy is associated with lower recurrence of non\u2013muscle-invasive bladder cancer. Eur Urol Focus. 2021;7(1):142\u20137. https:\/\/doi.org\/10.1016\/J.EUF.2019.04.021.","journal-title":"Eur Urol Focus"},{"issue":"2","key":"2059_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/J.JURO.2016.08.006","volume":"197","author":"M Shiota","year":"2017","unstructured":"Shiota M, Kiyoshima K, Yokomizo A, et al. Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5\u03b1-reductase inhibitor. J Urol. 2017;197(2):308\u201313. https:\/\/doi.org\/10.1016\/J.JURO.2016.08.006.","journal-title":"J Urol"},{"issue":"7","key":"2059_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.urolonc.2018.03.020","volume":"36","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, Fan Y, Jarosek SL, Lawrentschuk NL, Konety BR. Finasteride does not prevent bladder cancer: A secondary analysis of the medical therapy for prostatic symptoms study. Urologic Oncology: Seminars Original Investigations. 2018;36(7):338. .e13-338.e17.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"2","key":"2059_CR18","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clgc.2022.10.014","volume":"21","author":"H Garg","year":"2023","unstructured":"Garg H, Wheeler KM, Dursun F, et al. Impact of finasteride on survival in bladder cancer: A retrospective Multi-institutional database analysis. Clin Genitourin Cancer. 2023;21(2):314. .e1-314.e7.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2059_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/J.JURO.2018.04.082","volume":"200","author":"VJ M\u00e4kel\u00e4","year":"2018","unstructured":"M\u00e4kel\u00e4 VJ, Kotsar A, Tammela TLJ, Murtola TJ. Bladder cancer survival of men receiving 5\u03b1-reductase inhibitors. J Urol. 2018;200(4):743\u20138. https:\/\/doi.org\/10.1016\/J.JURO.2018.04.082.","journal-title":"J Urol"},{"issue":"5","key":"2059_CR20","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/J.AJPATH.2013.01.018","volume":"182","author":"JW Hsu","year":"2013","unstructured":"Hsu JW, Hsu I, Xu D, et al. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor. Am J Pathol. 2013;182(5):1811\u201320. https:\/\/doi.org\/10.1016\/J.AJPATH.2013.01.018.","journal-title":"Am J Pathol"},{"issue":"4","key":"2059_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/J.TRANON.2019.01.005","volume":"12","author":"D Sikic","year":"2019","unstructured":"Sikic D, Wirtz RM, Wach S, et al. Androgen receptor mRNA expression in urothelial carcinoma of the bladder: a retrospective analysis of two independent cohorts. Transl Oncol. 2019;12(4):661\u20138. https:\/\/doi.org\/10.1016\/J.TRANON.2019.01.005.","journal-title":"Transl Oncol"},{"issue":"8","key":"2059_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/S00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904. https:\/\/doi.org\/10.1007\/S00345-019-02984-4.","journal-title":"World J Urol"},{"issue":"3","key":"2059_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000474484","volume":"31","author":"S Imada","year":"1997","unstructured":"Imada S, Akaza H, Ami Y, Koiso K, Ideyama Y, Takenaka T. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol. 1997;31(3):360\u20134. https:\/\/doi.org\/10.1159\/000474484.","journal-title":"Eur Urol"},{"issue":"1","key":"2059_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/J.JURO.2012.02.2554","volume":"188","author":"M Shiota","year":"2012","unstructured":"Shiota M, Takeuchi A, Yokomizo A, et al. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol. 2012;188(1):276\u201386. https:\/\/doi.org\/10.1016\/J.JURO.2012.02.2554.","journal-title":"J Urol"},{"issue":"5","key":"2059_CR25","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/JC.2003-030330","volume":"89","author":"RV Clark","year":"2004","unstructured":"Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179\u201384. https:\/\/doi.org\/10.1210\/JC.2003-030330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2059_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/ERC-11-0010","volume":"18","author":"Y Zheng","year":"2011","unstructured":"Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer. 2011;18(4):451\u201364. https:\/\/doi.org\/10.1530\/ERC-11-0010.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2059_CR27","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-14-1055-T","volume":"14","author":"Z Shang","year":"2015","unstructured":"Shang Z, Li Y, Zhang M, et al. Antiandrogen therapy with hydroxyflutamide or androgen receptor degradation enhancer ASC-J9 enhances BCG efficacy to better suppress bladder cancer progression. Mol Cancer Ther. 2015;14(11):2586\u201394. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1055-T.","journal-title":"Mol Cancer Ther"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02059-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:55:45Z","timestamp":1771595745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02059-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2059"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02059-8","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval for the research was obtained from the Mersin University Faculty of Medicine Institutional Review Board (IRB) with the board decision dated July 10, 2024, and numbered 2024\/632. Written informed consent was required and obtained from all patients included in the study, as per the requirements of the Mersin University Faculty of Medicine IRB. The requirement for informed consent was not waived. All patient data were anonymized and de-identified prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}